Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

• Published in: Dermatology and therapy Vol. 13; no. 10; pp. 2473 - 2478
• Main Authors: Bartholomew, Erin, Chung, Bo-Young, Davis, Mitchell, Yeroushalmi, Samuel, Chung, Mimi, Hakimi, Marwa, Bhutani, Tina, Liao, Wilson
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.10.2023; Springer; Adis, Springer Healthcare
• Subjects: Anti-IL23; Case Report; Case studies; Complications and side effects; Dermatology; Drug therapy; Guselkumab; Guttate psoriasis; Internal Medicine; Medicine; Medicine & Public Health; Monoclonal antibody; Oral and Maxillofacial Surgery; Plastic Surgery; Psoriasis; Quality of Life Research; Remission; Sunburn; United States; Remission; Anti-IL23; Sunburn; Guttate psoriasis; Monoclonal antibody; Guselkumab
• ISSN: 2193-8210; 2190-9172
• DOI: 10.1007/s13555-023-01013-y

Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or chronic inflammatory skin disease. The guttate psoriasis was refractory to topical treatment. After the first dose of guselkumab (100 mg subcutaneous injection), the patient experienced near-clearance of her guttate psoriasis, with continued improvement and drug-free remission 8 months after cessation of treatment. Dermatologists could consider guselkumab as a treatment option for patients with guttate psoriasis. Future studies should examine the potential for guselkumab to induce drug-free remissions in guttate psoriasis.